Items where Author is "Biollaz, Jérôme"

2004

Csajka, Chantal and Marzolini, Catia and Fattinger, Karin and Décosterd, Laurent A. and Telenti, Amalio and Biollaz, Jérôme and Buclin, Thierry. (2004) Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy, 48 (9). pp. 3226-3232.

2003

Csajka, Chantal and Marzolini, Catia and Fattinger, Karin and Décosterd, Laurent A. and Fellay, Jacques and Telenti, Amalio and Biollaz, Jérôme and Buclin, Thierry. (2003) Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 73 (1). pp. 20-30.

2002

Marzolini, Catia and Rudin, Christoph and Decosterd, Laurent A. and Telenti, Amalio and Schreyer, Alain and Biollaz, Jérôme and Buclin, Thierry and Swiss Mother + Child HIV Cohort Study, . (2002) Transplacental passage of protease inhibitors at delivery. AIDS, 16 (6). pp. 889-893.

2001

Marzolini, Catia and Telenti, Amalio and Decosterd, Laurent A. and Greub, Gilbert and Biollaz, Jérôme and Buclin, Thierry. (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15 (1). pp. 71-75.

Marzolini, Catia and Chave, Jean-Philippe and Telenti, Amalio and Brenas-Chinchon, Laeticia and Biollaz, Jérôme. (2001) Impaired absorption of rifabutin by concomitant administration of didanosine. AIDS, 15 (16). pp. 2203-2204.

Marzolini, Catia and Buclin, Thierry and Decosterd, Laurent Arthur and Biollaz, Jérôme and Telenti, Amalio. (2001) Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Therapeutic drug monitoring, 23 (4). pp. 394-398.

1998

Marzolini, Catia and Decosterd, Laurent A. and Shen, Fei and Gander, Marc and Leyvraz, Serge and Bauer, Jean and Buclin, Thierry and Biollaz, Jérôme and Lejeune, Ferdy. (1998) Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer chemotherapy and pharmacology, 42 (6). pp. 433-440.